Putamen

Putamen

Introduction

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Putamen</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Dorsal Striatum, Basal Ganglia</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Lateral portion of the striatum, dorsal to the globus pallidus, lateral to the caudate nucleus</td>
</tr>
<tr>
<td class="label">Cell Types</td>
<td>Medium spiny [neurons](/entities/neurons) (D1 and D2), fast-spiking interneurons, low-threshold spiking interneurons, cholinergic interneurons</td>
</tr>
<tr>
<td class="label">Primary Neurotransmitters</td>
<td>GABA (output), Dopamine (modulation)</td>
</tr>
<tr>
<td class="label">Key Markers</td>
<td>DARPP32, D1R, D2R, PV (parvalbumin), Calbindin, Enkephalin</td>
</tr>
<tr>
<td class="label">Volume (human)</td>
<td>Approximately 5-6 cm³ total</td>
</tr>
<tr>
<td class="label">Cell Count</td>
<td>~100 million neurons in adult human</td>
</tr>
<tr>
<td class="label">Receptor Type</td>
<td>Pathway</td>
</tr>
<tr>
<td class="label">D1 (D1-MSNs)</td>
<td>Direct</td>
</tr>
<tr>
<td class="label">D2 (D2-MSNs)</td>
<td>Indirect</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>Putamen Involvement</td>
</tr>
<tr>
<td class="label">Multiple System Atrophy (MSA)</td>
<td>Striatal degeneration</td>
</tr>
<tr>
<td class="label">Progressive Supranuclear Palsy</td>
<td>[Tau](/proteins/tau) pathology in stri

Putamen

Introduction

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Putamen</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Dorsal Striatum, Basal Ganglia</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Lateral portion of the striatum, dorsal to the globus pallidus, lateral to the caudate nucleus</td>
</tr>
<tr>
<td class="label">Cell Types</td>
<td>Medium spiny [neurons](/entities/neurons) (D1 and D2), fast-spiking interneurons, low-threshold spiking interneurons, cholinergic interneurons</td>
</tr>
<tr>
<td class="label">Primary Neurotransmitters</td>
<td>GABA (output), Dopamine (modulation)</td>
</tr>
<tr>
<td class="label">Key Markers</td>
<td>DARPP32, D1R, D2R, PV (parvalbumin), Calbindin, Enkephalin</td>
</tr>
<tr>
<td class="label">Volume (human)</td>
<td>Approximately 5-6 cm³ total</td>
</tr>
<tr>
<td class="label">Cell Count</td>
<td>~100 million neurons in adult human</td>
</tr>
<tr>
<td class="label">Receptor Type</td>
<td>Pathway</td>
</tr>
<tr>
<td class="label">D1 (D1-MSNs)</td>
<td>Direct</td>
</tr>
<tr>
<td class="label">D2 (D2-MSNs)</td>
<td>Indirect</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>Putamen Involvement</td>
</tr>
<tr>
<td class="label">Multiple System Atrophy (MSA)</td>
<td>Striatal degeneration</td>
</tr>
<tr>
<td class="label">Progressive Supranuclear Palsy</td>
<td>[Tau](/proteins/tau) pathology in striatum</td>
</tr>
<tr>
<td class="label">Corticobasal Degeneration</td>
<td>Asymmetric putaminal atrophy</td>
</tr>
<tr>
<td class="label">Dementia with Lewy Bodies</td>
<td>Lewy body pathology</td>
</tr>
<tr>
<td class="label">Source</td>
<td>Neurotransmitter</td>
</tr>
<tr>
<td class="label">Motor [Cortex](/brain-regions/cortex)</td>
<td>Glutamate</td>
</tr>
<tr>
<td class="label">Premotor Cortex</td>
<td>Glutamate</td>
</tr>
<tr>
<td class="label">Supplementary Motor Area</td>
<td>Glutamate</td>
</tr>
<tr>
<td class="label">Somatosensory Cortex</td>
<td>Glutamate</td>
</tr>
<tr>
<td class="label">Thalamus (centromedian/parafascicular)</td>
<td>Glutamate</td>
</tr>
<tr>
<td class="label">Substantia Nigra pars compacta</td>
<td>Dopamine</td>
</tr>
<tr>
<td class="label">Raphe Nuclei</td>
<td>Serotonin</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Pathway</td>
</tr>
<tr>
<td class="label">Globus Pallidus externus (GPe)</td>
<td>D2-MSNs (indirect)</td>
</tr>
<tr>
<td class="label">Globus Pallidus internus (GPi)</td>
<td>D1-MSNs (direct)</td>
</tr>
<tr>
<td class="label">Substantia Nigra pars reticulata (SNr)</td>
<td>D1-MSNs (direct)</td>
</tr>
</table>

The Putamen is a large subcortical nucleus that forms the lateral portion of the striatum, the major input structure of the basal ganglia. As a critical component of the motor loop, the putamen is essential for movement initiation, execution, habit formation, and reward processing. This page provides comprehensive information about its anatomical structure, physiological functions, neurochemical properties, and pivotal role in neurodegenerative diseases, particularly Parkinson's disease (PD) and Huntington's disease (HD). [@graybiel2008]

Overview

Anatomical Structure

Location and Boundaries

The putamen is located in the basal ganglia, deep within the cerebral hemispheres:

• Anterior: Continuous with the head of the caudate nucleus (separated by the anterior limb of the internal capsule)
• Posterior: Borders the globus pallidus (external segment, GPe) laterally
• Superior: Adjacent to the external capsule and claustrum
• Inferior: Separated from the amygdala by the ansa lenticularis
• Lateral: Covered by the external capsule and extreme capsule

Cellular Composition

The putamen contains diverse neuronal populations:

Medium Spiny Neurons (MSNs)

• D1-MSNs (direct pathway): Express dopamine D1 receptors, substance P; project directly to the substantia nigra pars reticulata (SNr) and globus pallidus internus (GPi)
• D2-MSNs (indirect pathway): Express dopamine D2 receptors, enkephalin; project to the external segment of the globus pallidus (GPe)
• Account for ~90-95% of all neurons in the putamen
• Have dense [dendritic spines](/cell-types/dendritic-spines) ("spiny" appearance)

Interneurons

• Fast-spiking parvalbumin (PV) interneurons: Provide powerful inhibition to MSNs
• Low-threshold spiking (LTS) interneurons: Express somatostatin and neuropeptide Y
• Cholinergic interneurons (tonically active neurons, TANs): Release [acetylcholine](/entities/acetylcholine) and modulate MSN activity
• Account for ~5-10% of the neuronal population

Compartmental Organization

The putamen exhibits neurochemical compartmentalization:

• Striosomes: Patch-like compartments rich in μ-opioid receptors, D1 receptors, and substance P
• Matrix: Surrounding matrix compartments rich in calbindin, D2 receptors, and enkephalin
• These compartments may have different vulnerability in disease states

Physiological Functions

Motor Control

The putamen is a central hub for motor control:

• Movement initiation: Receives motor cortex input and initiates movement through the basal ganglia thalamocortical loops
• Movement scaling: Modulates the amplitude and force of movements
• Movement sequence execution: Controls sequential movements and procedural learning
• Motor habit formation: Critical for converting goal-directed actions into automatic habits [1]

Basal Ganglia Pathways

Direct Pathway (D1-MSNs)

• Facilitates wanted movements
• Dopamine D1 receptor activation promotes movement

Indirect Pathway (D2-MSNs)

• Suppresses unwanted movements
• Dopamine D2 receptor activation disinhibits movement

Reward Processing

The putamen processes reward-related information:

• Reinforcement learning: Signals reward prediction errors
• Habit formation: Converts reward-seeking behaviors into automatic habits
• Value-based decision making: Encodes the value of actions and outcomes
• Response to reward: Activates during receipt of expected and unexpected rewards

Cognitive Functions

Beyond motor control, the putamen contributes to:

• Working memory: Maintains task-relevant information
• Sequence learning: Encodes sequential patterns
• Category learning: Supports categorization of stimuli

Neurochemical Properties

Dopaminergic Modulation

Dopamine from the substantia nigra pars compacta (SNc) critically modulates putamen function:

GABAergic Output

MSNs produce GABA as their primary neurotransmitter:

• Projection targets: GPi, SNr, GPe
• Effect: Inhibitory, shaping basal ganglia output
• Pathology: Altered GABA signaling in HD and PD

Acetylcholine

Cholinergic interneurons (TANs) play important roles:

• Modulate MSN excitability
• Involved in reward learning
• Targeted in some therapeutic approaches

Role in Neurodegenerative Diseases

Parkinson's Disease

The putamen is severely affected in PD:

• Dopaminergic denervation: The putamen receives the densest dopaminergic innervation from the SNc, making it highly vulnerable to degeneration
• Neuronal loss: Up to 50-70% of putaminal MSNs are lost in advanced PD
• Pathology: Lewy bodies ([α-synuclein](/proteins/alpha-synuclein) aggregates) accumulate in putaminal neurons
• Functional consequences:
• Impaired movement initiation (bradykinesia)
• Increased muscle rigidity
• Resting tremor (via thalamic disinhibition)

Treatment Implications

• Levodopa: Restores dopamine in the putamen to improve motor symptoms
• Deep brain stimulation: GPi or STN stimulation modulates putaminal output
• Dopamine agonists: Directly stimulate D1/D2 receptors in the putamen

Huntington's Disease

The putamen shows early and severe degeneration in HD:

• MSN loss: Early preferential loss of D2-MSNs (indirect pathway)
• Neuropathology: Mutant [huntingtin](/proteins/huntingtin) protein aggregates in striatal neurons
• Clinical manifestations:
• Chorea (involuntary movements)
• Dystonia
• Cognitive decline
• Striosome vulnerability: Early degeneration of striosome compartments

Other Neurodegenerative Conditions

Connectivity Map

Afferent Inputs (Inputs to Putamen)

Efferent Outputs (Outputs from Putamen)

Research Methods

Neuroimaging

• MRI: Structural imaging to measure putaminal volume and atrophy
• Diffusion Tensor Imaging (DTI): Assess white matter integrity
• fMRI: Functional activation during motor and cognitive tasks
• PET: Dopamine transporter binding, glucose metabolism

Electrophysiology

• Intracellular recordings: Characterize MSN membrane properties
• Extracellular unit recordings: Single-neuron activity in vivo
• Local field potentials (LFPs): Oscillatory activity in the basal ganglia

Molecular Methods

• Immunohistochemistry: Protein localization
• In situ hybridization: Gene expression patterns
• Single-cell RNA-seq: Transcriptomic profiling

Clinical Assessment

Diagnostic Tools

• MRI: Rule out structural lesions, assess atrophy patterns
• DaTSPECT: Dopamine transporter imaging (reduced in PD)
• FDG-PET: Metabolic patterns (reduced putaminal metabolism in PD)
• CSF biomarkers: α-synuclein, tau, amyloid

Clinical Scales

• UPDRS (Unified Parkinson's Disease Rating Scale): Motor examination
• Huntington's Disease Rating Scale: Motor and cognitive assessment
• Timed Up and Go: Functional mobility

Therapeutic Approaches

Pharmacological

• Dopamine precursors (Levodopa): Bypass degenerated SNc
• Dopamine agonists: Bromocriptine, pramipexole, rotigotine
• MAO-B inhibitors: Selegiline, rasagiline
• COMT inhibitors: Entacapone, tolcapone

Surgical

• Deep Brain Stimulation (DBS): GPi or STN targets
• Lesioning: Pallidotomy, thalamotomy
• Cell transplantation: Dopaminergic cell replacement (experimental)

Emerging

• Gene therapy: AAV-based gene delivery
• Immunotherapy: α-synuclein-targeted antibodies
• Neuroprotective agents: Disease-modifying compounds

See Also

• [Caudate Nucleus](/cell-types/caudate-nucleus) — Adjacent striatal structure
• [Striatum](/brain-regions/striatum) — Overview of the striatum
• [Globus Pallidus](/brain-regions/globus-pallidus) — Output structure
• [Substantia Nigra](/brain-regions/substantia-nigra) — Dopamine source
• [Parkinson's Disease](/diseases/parkinsons-disease) — PD overview
• [Huntington's Disease](/diseases/huntington-disease) — HD overview
• [Basal Ganglia Circuitry](/entities/basal-ganglia-circuitry) — Motor loop details
• [Dopamine Signaling](/mechanisms/dopamine-signaling) — Neurotransmitter pathways

Background

The study of Putamen has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

Pathway Diagram

The following diagram shows the key molecular relationships involving Putamen discovered through SciDEX knowledge graph analysis:

Pathway Diagram

The following diagram shows the key molecular relationships involving Putamen discovered through SciDEX knowledge graph analysis: